Novo improves outlook on continued demand for Wegovy pill, Ozempic (NVO:NYSE)
· seekingalpha.com
Novo lifts outlook as Wegovy and Ozempic boost GLP-1 sales.
Novo (NVO) raised its outlook for the year once again, driven by continued demand for its Wegovy weight-loss pill, and its older shot Ozempic.
The Danish drugm...